<i>MYC</i> translocation, <i>KMT2A</i> (<i>MLL</i>) amplification, and 5q/20q losses suggest secondary therapy-related AML and categorize this case in the adverse risk prognosis under the ELN 2022 guidelines. This evidence concerns the gene MYC and acute myeloid leukemia.